Analytical Data
-
基因名
IL15
- Application
-
别名
IL15；Interleukin-15
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P40933
-
表达区间
49-162aa
-
氨基酸序列
NWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVI SLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFL QSFVHIVQMFINTS
-
分子量
13 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-15 (IL-15) is a pivotal cytokine involved in the regulation of immune responses, specifically in the proliferation and activation of natural killer (NK) cells and CD8+ T cells. Due to its critical role in enhancing immune surveillance and response, IL-15 has garnered significant attention in the field of immunotherapy, particularly for cancer treatment and viral infections. The recombinant IL-15 protein has been developed to exploit its therapeutic potential, enabling researchers to study its biological functions and explore its applications in clinical settings. In various preclinical and clinical trials, recombinant IL-15 has demonstrated the ability to boost the efficacy of immune responses and improve anti-tumor activity, leading to prolonged survival rates in patients with malignancies. Moreover, IL-15's synergistic effects with other therapies, such as checkpoint inhibitors and adoptive cell transfer, have underscored its importance as a promising immunomodulatory agent. Investigating its recombinant forms aids in understanding the precise mechanisms of IL-15's action, optimizing dosing strategies, and evaluating combination therapies, thus paving the way for innovative treatment paradigms in oncology and infectious diseases.
